LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in i

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that the Ministry

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno

ImageneBio (NASDAQ: IMA - Get Free Report) and Agenus (NASDAQ: AGEN - Get Free Report) are both smal

Agenus (NASDAQ: AGEN - Get Free Report)'s stock had its "buy" rating reiterated by equities research

Survival estimate remained at 48% between years two and three, extending evidence of durable benefit

[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced thr

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-on

[url="]Agenus Inc.[/url] (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced tha

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that two posters

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-onc

U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial

Rodman & Renshaw analyst Michael King initiates coverage on Agenus (NASDAQ:AGEN) with a Buy r

Chardan Capital analyst Andreas Argyrides initiates coverage on Agenus (NASDAQ:AGEN) with a Buy r

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovatio

Agenus Inc. (NASDAQ: AGEN - Get Free Report)'s stock price passed above its 200-day moving average d

[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced tha

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-onc

[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovatio

[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the

No colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 2

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-onc

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losse

HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and lowers

Agenus (AGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate

Agenus (NASDAQ:AGEN) reported quarterly sales of $34.500 million which beat the analyst consensus es

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-onc

B. Riley Securities analyst Mayank Mamtani maintains Agenus (NASDAQ:AGEN) with a Buy and raises t

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncolog

Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the lates

U.S. stock futures were mixed on Tuesday, as the Nasdaq 100 index advanced, while the Dow Jones and

ORCL, VEEE, AGEN, MU, SNDK were among the stocks seen trending on Monday, July 13, 2026.

Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session

US stocks dip, Nasdaq falls 1%. Dow down 0.34%. Energy shares up 2.1%, tech down 1.2%. Micron Tech d

HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and raises

Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M f

Agenus stock surged 100%, after the biotech secured up to $340 million in fresh capital, extended it

US stocks mixed, Dow up 100 points. Energy up 2.1%, tech down 1.1%. LogProstyle Inc shares rise on e

Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke

QTTB: 82% | Q32 Bio shares are trading higher after the company it will report 36-week topline resul

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that it has enter

Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% thre

Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b studyAgenus

First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resiste

Noetik's TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated

Published prospective cohort showed durable responses and manageable safety in patients with HCC fol